Slide 1: Investor Relations
Investor Relations February 14, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2022 guidance, 2025 targets, growth targets, other expectations and other non-historical information.
Slide 3: Vision: The Autonomous Pharmacy
VISION The Autonomous Pharmacy will transform the pharmacy care delivery model by enabling the provider to practice at the top of their license. © 2022 Omnicell, Inc. 3
Slide 4: Delivering Strong Results and Building Momentum
Delivering Strong Results and Building Momentum Projected Long-Term Value Upside FY 2021 Actuals Clear leadership position in the digital transformation of healthcare with $70B+ Total Addressable Market (TAM) $1.217B $1.133B $230M $3.81 Product Bookings Total Non-GAAP Revenue Non-GAAP EBITDA Non-GAA
Slide 5: Well-Positioned for Continued Growth and Shareholder Value Creation
Well-Positioned for Continued Growth and Shareholder Value Creation 1 2 3 4 Category creator Leading strategic partner Resilient, high-visibility Demonstrated track positioned to transform to health systems in large revenue accelerated by record of growth and the pharmacy care and growing market hig
Slide 6: Omnicell Provides Solutions for an Expensive and Error-Prone Medication Management Reality
1 Omnicell Provides Solutions for an Expensive and Error-Prone Medication Management Reality Medication Management is Expensive and Error-Prone Omnicell's Current Solutions Deliver Results6 25,000 4 47 million 1 Enhanced 99.999997% Safety Errors Annually Errors Per Day in Doses Lost to Error Per 200
Slide 7: Autonomous Pharmacy Framework
1 Autonomous Pharmacy Framework Increasing healthcare value In 2019, leading health systems jointly created a framework analyzing the technological maturity of pharmacies The group determined there was a significant opportunity to drive greater healthcare value The group established a 5-level framew
Slide 8: Omnicell's Autonomous Pharmacy is a New Category of Solutions
1 Omnicell’s Autonomous Pharmacy is a New Category of Solutions That Fundamentally Improves Provider Outcomes Omnicell One™ CPDS IVCS EnlivenHealth® Omnicell340B ReCept Future Services1 One Platform Omnicell Future Devices1 Connected Devices XT Automated Anesthesia XR2 Robot IV Robot IVX Workflow Di
Slide 9: Leader in Large and Growing Segments
2 Leader in Large and Growing Segments Omnicell is growing its leadership position across a $70B+ TAM Estimated TAM Opportunity1 Key Advanced Services Point of Care $20B Omnicell One™ CPDS Central Pharmacy $15B Omnicell 340B IVCS 340B Software – Enabled Services $12B Retail, Institutional and Payers
Slide 10: Resilient and High-Visibility Revenue
3 Resilient and High-Visibility Revenue Connected Devices, Software Licenses & Other4 Recurring Technical Services and Other Recurring6 Recurring SaaS, Subscription Software & Tech-Enabled Services5 Robust Robust product backlog Backlog ~25% Deep 151 of the top 300 U.S. health ~10% Customer systems
Slide 11: Accelerating Recurring Revenue Growth
3 Advanced Services Accelerating Recurring Revenue Growth Leveraging established channel SaaS, Subscription Software & Tech-Enabled and strong customer relationships Services (% of Total Revenue) 20-30% Strong demand driven by increasing ✓ Targeting 15% of provider digitization and need to evolve me
Slide 12: Driving Profitable Growth Through Disciplined Execution
4 Driving Profitable Growth Through Disciplined Execution Expected Annual Revenue ($ in Millions) $1,900-$2,000 $1,650- $1,750 Execute value-enhancing M&A $1,133 Drive innovation and continue to deliver the Autonomous Pharmacy Vision Continue market share gains Capitalize on upgrade cycles Continue
Slide 13: Continuing to Drive Margin Expansion
4 Continuing to Drive Margin Expansion Key Drivers of Margin Enhancement2 Improving Business Mix – SaaS, Subscription Targeted Non-GAAP Operating Margin (%) Software & Tech-Enabled Services targeted to represent 20-30% of revenue by 2025, supporting ~21% strong gross margins 16.3% Long-Term Customer
Slide 14: Building on Our Track Record of Delivering Shareholder Value
4 Building on Our Track Record of Delivering Shareholder Value Omnicell’s Total Shareholder Return Time Period Omnicell (OMCL) S&P Healthcare (XLV) Outperformance 1 Year +19% +17% +2% 3 Year +105% +58% +47% 5 Year +323% +104% +219% 10 Year +853% +341% +512% Omnicell has outperformed the S&P Healthca
Slide 15: Well-Positioned for Continued Growth and Shareholder Value Creation
Well-Positioned for Continued Growth and Shareholder Value Creation 1 Category creator positioned to transform the pharmacy care delivery model Large portion of the healthcare sector: $1,331B annually globally 2 Leading strategic partner to health systems in large and growing market segments Clear l
Slide 16: Financial Guidance
Financial Guidance Includes the anticipated contributions of ReCept, MarkeTouch Media, and the previously-acquired FDS Amplicare, as well as the anticipated effects of the current inflationary environment. Q1 2022 FY 2022 Product Bookings Not Provided $1.370 - 1.430 Billion Total GAAP and Non-GAAP R
Slide 17: Appendix
Appendix 17
Slide 18: Omnicell Delivers a Suite of Innovative Solutions
Omnicell Delivers a Suite of Innovative Solutions Service Technical Services Professional Services Advisory Services Outcomes Outcomes Omnicell One™ Safety + Intelligence Omnicell 340B 340B Analysis Inventory Analytics Diversion Management Compliance EnlivenHealth™ Financial Savings Operational + Su
Slide 19: Winning Go-To-Market Strategy
Winning Go-To-Market Strategy Long-term strategic partnerships with key customers Over half of the Top 300 U.S. Health Systems1 are current Omnicell customers 151 of those have entered into long-term sole source partnership agreements with Omnicell2 Multiyear co-development plans with the majority o
Slide 20: Multiyear Co-Development Plan Example: Large Health System Customer
Multiyear Co-Development Plan Example: Large Health System Customer Year 1 Year 2 Year 3 Year 4/5 KPI New Hospital Safety Efficiency Medical Center 1 Safety Efficiency University Campus People Compliance Medical Center 2 Safety Efficiency Medical Center 3 Safety Efficiency Medical Center 4 Financial
Slide 21: Point of Care (Only) Replacement Bookings
Point of Care (Only) Replacement Bookings $1,200 60% 55% 48% $1,000 50% 43% 39% $800 40% 36% Cumulative Bookings in $ 30% Cumulative % of Millions $600 26% 30% TAM Captured 1 24% 23% $400 18% 20% 15% 11% 13% $200 8% 10% 5% 6% $0 0% 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q2
Slide 22: Omnicell's Strategic Approach to Corporate Responsibility
Environment Innovating for Energy Efficiency Integrate Omnicelts sustainable Procurement strategies across 700% of our Tier 1 High Risk suppliers by 2025. ‘Conduct a Scope 1 & 2 cimate Reduce scope 1 & 2 emissions by 25% by 2027 Establish Scope 3 reduction targets by 2030 network (customers) by 2025
Slide 23: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Year Ended December 2021 Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues S$ 1132018 $ 892,208 Acquisiti ing impact related to 780 Non-GAAP revenues S128 7S 392208 Rec
Slide 24: Reconciliation of GAAP to Non-GAAP
‘Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) ‘Year Ended December 31, 2021 Reconciliation of GAAP net income to non-GAAP net income: GAAP net income s 77349 $ 32,194 Tax impact of IP restructuring (6202) . Share-based. 53,160 44,6
Slide 25: Reconciliation of GAAP operating cash flow to free cash flow
(© 2022 Ompicell ne Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow: GAAP net cash provided by operating activities Software development for extemal use Purchases of property and equipment Non-GAAP free cash flow Year Ended December 31, 2021 2020 231,809 $
Slide 26: Slide 26